Disc Medicine (IRON) to Release Quarterly Earnings on Thursday

Disc Medicine (NASDAQ:IRON) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Disc Medicine to post earnings of ($1.06) per share for the quarter.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.08. On average, analysts expect Disc Medicine to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Disc Medicine Trading Up 0.5 %

NASDAQ:IRON opened at $51.27 on Tuesday. The company’s 50-day moving average price is $55.95 and its 200-day moving average price is $56.03. The company has a market cap of $1.77 billion, a P/E ratio of -12.88 and a beta of 0.73. Disc Medicine has a twelve month low of $25.60 and a twelve month high of $68.86.

Insider Buying and Selling at Disc Medicine

In related news, Director Mona Ashiya sold 202,146 shares of Disc Medicine stock in a transaction on Monday, March 10th. The stock was sold at an average price of $54.29, for a total value of $10,974,506.34. Following the completion of the transaction, the director now directly owns 208,742 shares in the company, valued at approximately $11,332,603.18. This trade represents a 49.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Jean M. Franchi sold 3,136 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $171,162.88. Following the sale, the chief financial officer now owns 69,530 shares in the company, valued at approximately $3,794,947.40. This trade represents a 4.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 346,617 shares of company stock worth $19,182,953 over the last three months. Insiders own 4.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $90.00 price target (up from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. HC Wainwright restated a “buy” rating and set a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday, January 21st. Scotiabank raised their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 3rd. Morgan Stanley restated an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research report on Friday, March 7th. Finally, TD Cowen started coverage on shares of Disc Medicine in a research report on Thursday, February 27th. They set a “buy” rating for the company. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $89.10.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.